TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31370791

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Confidence interval/band based approaches
Number of subjects: 0
Study: 29206782

Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (C)
Number of subjects: 16
Study: 27405859

Group type: EXPERIMENTAL
Intervention: Conscious sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study: 25301896

Group type: EXPERIMENTAL
Intervention: NO3 (‐) supplementation (beetroot juice, 8.2 mmol/day NO3 (‐))
Number of subjects: 8
Study: 23734518

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 83
Study: 20307043

Group type: EXPERIMENTAL
Intervention: Phaco-chop technique
Number of subjects: 102

Group type: COMPARATOR
Intervention: Stop-and-chop technique
Number of subjects: 102
Study: 16981899

Group type: EXPERIMENTAL
Intervention: 500 microg of intravenous beclomethasone monopropionate (17-BMP) for 15 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 microg of intravenous beclomethasone monopropionate (17-BMP) for 2 h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 8
Study: 15956631

Group type: EXPERIMENTAL
Intervention: Invasive strategy based on coronary stenting with abciximab
Number of subjects: 365

Group type: COMPARATOR
Intervention: Conservative treatment strategy
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 365

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 365
Study: 14712987

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogen, 0.625 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patches, 50 microg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: No hormones
Number of subjects: 90
Study: 10737822

Group type: EXPERIMENTAL
Intervention: Mandatory urine drug screening
Number of subjects: 392

Group type: COMPARATOR
Intervention: Usual-care (clinical judgment based)
Number of subjects: 392
Study: 8855811

Group type: EXPERIMENTAL
Intervention: Estradiol replacement therapy (micronized estradiol [Estrace TM], 2 mg orally each day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both arms (estradiol and control)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Estradiol replacement therapy (in subset with less than 3 months of amenorrhea)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No therapy (in subset with greater than 3 months of amenorrhea)
Number of subjects: 37
Study: 1643806

Group type: EXPERIMENTAL
Intervention: Healthy living advice (diet and physical activity) over 6 months (n = 23)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Healthy living advice (diet and physical activity) over 2 years (n = 17 reassessed)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (n = 8, 7 examined)
Number of subjects: 31
Study: 6379570

Group type: EXPERIMENTAL
Intervention: Intravenous cefamandole, 1.5 g before incision followed by 1.5 g every four hours up to the 24th postoperative hour
Number of subjects: 84

Group type: COMPARATOR
Intervention: No antibiotic (control group K-)
Number of subjects: 84
Study: 31045590

Group type: EXPERIMENTAL
Intervention: Curcumin (3000 mg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 28626868

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg meperidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2 ml of normal saline (Control)
Number of subjects: 90
Study: 24681422

Group type: EXPERIMENTAL
Intervention: Public CLABSI reporting begun by 2006
Number of subjects: 4705857

Group type: EXPERIMENTAL
Intervention: Public CLABSI reporting begun by 2009
Number of subjects: 4705857

Group type: COMPARATOR
Intervention: Never reporting states
Number of subjects: 4705857
Study: 23746558

Group type: EXPERIMENTAL
Intervention: Fructose-rich mixed meal (30% of calories from fructose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucose-rich mixed meal (30% of calories from glucose)
Number of subjects: 12
Study: 21242793

Group type: EXPERIMENTAL
Intervention: Enhanced cleaning of the near-patient environment (twice-daily for 2 months)
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Enhanced cleaning (doctors' hands)
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Enhanced cleaning (nurses' hands)
Number of subjects: 2583

Group type: COMPARATOR
Intervention: Standard cleaning
Number of subjects: 2583
Study: 18271889

Group type: EXPERIMENTAL
Intervention: Saffron 30 mg/day (15 mg twice a day; morning and evening)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (twice a day)
Number of subjects: 100
Study: 17192685

Group type: EXPERIMENTAL
Intervention: Sanazole biweekly 1.25 g intravenous infusion 15 minutes before radiotherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline infusion (control)
Number of subjects: 46
Study: 14578723

Group type: EXPERIMENTAL
Intervention: Restricted intravenous fluid regimen
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard intravenous fluid regimen
Number of subjects: 172
Study: 11072938

Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin E
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 8969353

Group type: EXPERIMENTAL
Intervention: EMLA cream (2.5% lidocaine, 2.5% prilocaine) applied 1 hour before phlebotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo applied 1 hour before phlebotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 0
Study: 1472142

Group type: EXPERIMENTAL
Intervention: Garlic powder preparation (900 mg daily for 6 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Garlic powder preparation
Number of subjects: 24
Study: 6367749

Group type: EXPERIMENTAL
Intervention: goal‐oriented outreach rehabilitation program
Number of subjects: 57

Group type: COMPARATOR
Intervention: usual treatment
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: assistive devices and home modifications
Number of subjects: 57
Study: 29575788

Group type: EXPERIMENTAL
Intervention: Tidal Peritoneal Dialysis (TPD)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Continuous Venovenous Hemodiafiltration (CVVHDF)
Number of subjects: 125
Study: 26570994

Group type: EXPERIMENTAL
Intervention: Fish oil (omega-3) 3 g/day, taken 3 times a day for 90 days
Number of subjects: 63

Group type: COMPARATOR
Intervention: Mineral oil (placebo) 3 g/day, taken 3 times a day for 90 days
Number of subjects: 63
Study: 24247760

Group type: EXPERIMENTAL
Intervention: Escherichia coli strain Nissle 1917 (EcN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23442582

Group type: EXPERIMENTAL
Intervention: Killed whole-virus HIV vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic HBV vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New tuberculosis vaccine candidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenB vaccine Bexsero
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccine
Number of subjects: 0
Study: 19845667

Group type: EXPERIMENTAL
Intervention: 4% niacinamide + 2% NAG in SPF 15 sunscreen moisturizing lotion and evening moisturizing cream (test formulation)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Vehicle control (SPF 15 lotion and cream vehicles)
Number of subjects: 202
Study: 19058684

Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching + Prime & Bond NT
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching + Single Bond
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: FL Bond
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Mac Bond II
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: One Up Bond F
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching only
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Helioseal F applied alone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Etch‐and‐rinse adhesives
Number of subjects: 192
Study: 16639484

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/weekly + salazopyrin 2 g/daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/weekly + infliximab 3 mg/Kg at time 0, 2, 4 and every 8 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/weekly + etanercept 25 mg/twice weekly
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/weekly + adalimumab 40 mg/every other week
Number of subjects: 80
Study: 11834533

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg per day for 4 months)
Number of subjects: 76
Study: 9892883

Group type: EXPERIMENTAL
Intervention: Propantheline (15 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 18
Study: 7527493

Group type: EXPERIMENTAL
Intervention: Transurethral surgery
Number of subjects: 556

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 556
Study: 2076384

Group type: EXPERIMENTAL
Intervention: Pindolol (0.015 mg/kg intravenously)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (0.1 mg/kg intravenously)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/day orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg/day orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (intravenous)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pindolol (intravenous)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (oral)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pindolol (oral)
Number of subjects: 10
Study: 7361794

Group type: EXPERIMENTAL
Intervention: Rectal thiopental (25-45 mg/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intramuscular cocktail (2.0 mg/kg meperidine, 1.0 mg/kg chlorpromazine, 1.0 mg/kg promethazine)
Number of subjects: 72
Study: 31742795

Group type: EXPERIMENTAL
Intervention: Resisted sled pushing (light, moderate, heavy resistance)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unresisted sled pushing
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resisted sled pushing (heavy load)
Number of subjects: 50
Study: 30210103

Group type: EXPERIMENTAL
Intervention: Display group (charges displayed)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-display group (charges not displayed)
Number of subjects: 27
Study: 25579006

Group type: EXPERIMENTAL
Intervention: Superior joint space injection of hyaluronic acid (HA)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Inferior joint space injection of hyaluronic acid (HA)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Comparison between superior and inferior groups
Number of subjects: 141
Study: 24952864

Group type: EXPERIMENTAL
Intervention: ADRC treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 21956636

Group type: EXPERIMENTAL
Intervention: Experimental coated catheter (with athrombogenic Camouflage® layer)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard uncoated catheter
Number of subjects: 179
Study: 19164343

Group type: EXPERIMENTAL
Intervention: 5 mg desloratadine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg montelukast
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of desloratadine and montelukast
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17907854

Group type: EXPERIMENTAL
Intervention: Treatment for Adolescents with Depression Study (TADS)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Five classes of symptoms identified through latent profile analysis
Number of subjects: 423
Study: 15355145

Group type: EXPERIMENTAL
Intervention: Stimulus images that reverse or remove the inclusion relationship
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cat images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dog images
Number of subjects: 0
Study: 11228580

Group type: EXPERIMENTAL
Intervention: CT venography with caudocranial acquisition starting at 210 seconds
Number of subjects: 50
Study: 10216325

Group type: EXPERIMENTAL
Intervention: Template-assisted documentation (T-System)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Undirected written documentation
Number of subjects: 1228
Study: 8549577

Group type: EXPERIMENTAL
Intervention: Continuous contractions (CC) - 30 seconds with 1-minute rest
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intermittent contractions (IC) - 3 seconds with 2 seconds rest
Number of subjects: 7
Study: 2108885

Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate depot
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 7.5 mg leuprorelin acetate depot
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 15 mg leuprorelin acetate depot
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 3.75 mg, 7.5 mg, and 15 mg leuprorelin acetate depot
Number of subjects: 22
Study: 518076

Group type: EXPERIMENTAL
Intervention: Aminoglycosides (n=124)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Aminoglycosides (nephrotoxic patients, n=30)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control (other antibiotics, n=30)
Number of subjects: 154
Study: 30846896

Group type: COMPARATOR
Intervention: Lippes loop intrauterine device (IUD) only
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: IUD plus a new crosslinked hyaluronan (NCH) gel
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: NCH gel only
Number of subjects: 72

Group type: COMPARATOR
Intervention: IUD only
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: IUD plus NCH
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: NCH only
Number of subjects: 72
Study: 28159944

Group type: EXPERIMENTAL
Intervention: Maternal voice group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 25750038

Group type: EXPERIMENTAL
Intervention: 5-minute group
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 10-minute group
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 15-minute group
Number of subjects: 256

Group type: COMPARATOR
Intervention: Overall success rates
Number of subjects: 256

Group type: COMPARATOR
Intervention: Post-ERCP pancreatitis (PEP)
Number of subjects: 256
Study: 23916465

Group type: EXPERIMENTAL
Intervention: RelyX™ Unicem(®) (3M)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MIP(®)/Transbond Supreme Low Viscosity(®) (3M)
Number of subjects: 16
Study: 21507924

Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentrations
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentrations in subgroups with previous lapses in adherence
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentrations in subgroups with low hair levels
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentrations in subgroups with detectable viremia
Number of subjects: 424
Study: 19843321

Group type: EXPERIMENTAL
Intervention: XanGo Juice 18 oz twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: XanGo Juice 3 oz twice daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: XanGo Juice 6 oz twice daily
Number of subjects: 44
Study: 17111232

Group type: EXPERIMENTAL
Intervention: TACE-RFA
Number of subjects: 83

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 83
Study: 14644283

Group type: EXPERIMENTAL
Intervention: Continuous Pringle maneuver
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inflow plus outflow vascular occlusion
Number of subjects: 40
Study: 10874268

Group type: EXPERIMENTAL
Intervention: Initial understanding score
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repeat understanding score
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Initial knowledge of potential benefit
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Initial knowledge of risk
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repeat knowledge of risk
Number of subjects: 20
Study: 9032592

Group type: EXPERIMENTAL
Intervention: IPM/CS monotherapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: IPM/CS combination therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: IPM/CS combination therapy with other antibiotics (not penicillins, cephalosporins, or aminoglycosides)
Number of subjects: 109
Study: 1523286

Group type: EXPERIMENTAL
Intervention: Diazepam (15 or 20 mg orally)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lorazepam (1.75 or 2.5 mg orally)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6498137

Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone acetonide
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional incision and curettage
Number of subjects: 69
Study: 3946771

Group type: EXPERIMENTAL
Intervention: Hyoscine patch applied to the skin behind one ear
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo patch applied to the skin behind one ear
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hyoscine patch
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 42
Study: 31732705

Group type: EXPERIMENTAL
Intervention: PIF8 in far-red light
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PIF8 protein accumulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PIF3 protein accumulation
Number of subjects: 0
Study: 29620914

Group type: EXPERIMENTAL
Intervention: Metformin (500-850 mg given twice a day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Metformin (open-label from week 17 to week 32)
Number of subjects: 51
Study: 27140068

Group type: EXPERIMENTAL
Intervention: Mobile healthcare application
Number of subjects: 89

Group type: COMPARATOR
Intervention: Poster
Number of subjects: 89
Study: 25325484

Group type: EXPERIMENTAL
Intervention: Home single-channel nasal pressure with manual scoring
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Home single-channel nasal pressure with automatic scoring
Number of subjects: 787

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 787
Study: 22564018

Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Number of subjects: 80
Study: 20865841

Group type: EXPERIMENTAL
Intervention: LGP‐HA + L (Lidocaine hydrochloride 2%)
Number of subjects: 18

Group type: COMPARATOR
Intervention: LGP‐HA (Control)
Number of subjects: 18
Study: 18467288

Group type: EXPERIMENTAL
Intervention: Homecare referral
Number of subjects: 375

Group type: COMPARATOR
Intervention: No homecare referral
Number of subjects: 375
Study: 15671427

Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 15570
Study: 12656456

Group type: EXPERIMENTAL
Intervention: Toto ointment alone
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Combination of Toto ointment and soap
Number of subjects: 595

Group type: COMPARATOR
Intervention: Sulfur ointment alone
Number of subjects: 595
Study: 12697510

Group type: EXPERIMENTAL
Intervention: Head down tilt (‐6 degrees HDT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Upright control position
Number of subjects: 8
Study: 8679235

Group type: EXPERIMENTAL
Intervention: Adenosine echocardiography alone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Adenosine echocardiography with handgrip
Number of subjects: 67

Group type: COMPARATOR
Intervention: Exercise echocardiography
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Adenosine echocardiography
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Adenosine echocardiography with and without handgrip
Number of subjects: 67
Study: 1905960

Group type: EXPERIMENTAL
Intervention: Emulsion A (Intralipid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Emulsion B (Tutolipid)
Number of subjects: 20
Study: 6132220

Group type: EXPERIMENTAL
Intervention: Sealed catheters
Number of subjects: 220

Group type: COMPARATOR
Intervention: Unsealed catheters
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Sealed catheters among patients receiving systemic antibiotics
Number of subjects: 220

Group type: COMPARATOR
Intervention: Unsealed catheters among patients receiving systemic antibiotics
Number of subjects: 220
Study: 30159604

Group type: EXPERIMENTAL
Intervention: Pennebaker's expressive writing intervention (EWI)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 71
Study: 29690736

Group type: EXPERIMENTAL
Intervention: Analgesic and sedative treatment for 24 hours besides conventional treatment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Analgesic and sedative treatment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 180
Study: 26890974

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee plus 5 mg.kg anhydrous caffeine (D + C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (COF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Anhydrous caffeine (CAF)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (DEC)
Number of subjects: 9
Study: 26396949

Group type: EXPERIMENTAL
Intervention: Narivent(®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical intranasal corticosteroid
Number of subjects: 40
Study: 22951921

Group type: EXPERIMENTAL
Intervention: Matched-bias (MB) exercises
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unmatched-bias (UB) exercises
Number of subjects: 33
Study: 20577273

Group type: EXPERIMENTAL
Intervention: Standard‐fluence verteporfin photodynamic therapy (PDT) + ranibizumab
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham (control) + ranibizumab
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (PDT and sham)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PDT group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 18
Study: 17472600

Group type: EXPERIMENTAL
Intervention: Selenica R
Number of subjects: 24

Group type: COMPARATOR
Intervention: Depakene R
Number of subjects: 24